GRCL News and Press, Gracell Biotechnologies Inc. From 01/19/21

Gracell Biotechnologies Receives IND Approval from China NMPA for GC019F, a FasTCAR-Enabled CAR-T Therapy for the Treatment of Relapsed or Refractory Adult B-ALL PR Newswire SUZHOU and SHANGHAI, China , Jan. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (...

BeiGene out-licensed ex-China rights for tislelizumab, its China-approved anti-PD-1 antibody, to Novartis in a $2.2 billion agreement. Inmagene in-licensed global rights to four novel pre-clinical immunological candidates from Hutchison China MediTech in a deal that has a potential va...

Gracell Biotechnologies (GRCL) has been granted the Medical Products Manufacturing Certificate ((MPMC)) from the Jiangsu Medical Products Administration in China for its CAR-T cell therapy products.The certification was granted on January 4, 2021, and indicates that Gracell's site in Suz...

China NMPA Grants Approval for the Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL PR Newswire SUZHOU and SHANGHAI, China , Jan. 13, 2021 /PRNewswire/ --  Gracell Biotech...